Published in Semin Oncol on December 01, 1977
Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med (1974) 2.77
A clinical review of bleomycin--a new antineoplastic agent. Cancer (1973) 2.53
The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev (1975) 2.10
Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med (1973) 2.01
Pancreatic islet cell carcinoma. I. Clinical features of 52 patients. Ann Intern Med (1973) 1.87
Adriamycin-a review. J Natl Cancer Inst (1975) 1.68
The chemotherapy of urologic cancer. Cancer (1975) 1.32
Integration of chemotherapy into combined modality treatment of solid tumors VII. Adenocarcinoma of the breast. Cancer Treat Rev (1976) 1.31
Carboplatin: the clinical spectrum to date. Cancer Treat Rev (1985) 1.27
The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol (1972) 1.24
Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res (1975) 1.22
Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med (1983) 1.19
Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res (1986) 1.17
The dilemma of adjuvant chemotherapy for osteogenic sarcoma. Cancer Clin Trials (1980) 1.16
Management of locally advanced and disseminated breast cancer. Lancet (1981) 1.13
Surgery plus adjuvant chemotherapy--a review of therapeutic implications. I. Breast cancer. Cancer Chemother Pharmacol (1980) 1.11
A review of chemotherapy in gastric cancer. Cancer (1974) 1.09
An overview of the 1978 international meeting on comparative therapeutic trials. Biomedicine (1978) 1.08
A comparison of the quality of participation of community affiliates and that of universities in the Northern California Oncology Group. J Clin Oncol (1983) 1.07
Single and combination nonhormonal chemotherapy in breast cancer. Cancer (1972) 1.06
Adjuvant chemotherapy in lung cancer: review and prospects. Cancer (1977) 1.02
Glutamine antagonists in chemotherapy. Adv Pharmacol Chemother (1970) 1.01
Hexamethylmelamine. An evaluation of its role in the therapy of cancer. Cancer (1976) 1.00
Management of trials in the development of cancer chemotherapy. Br J Cancer (1978) 0.99
Calibrated phase II clinical trials in oncology. Stat Med (1987) 0.99
Integration of chemotherapy into combined modality therapy of solid tumors. IV. Malignant melanoma. Cancer Treat Rev (1974) 0.98
5-(3,3-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388)--a new antitumor agent with activity against malignant melanoma. Eur J Cancer (1972) 0.97
Nafoxidine--an antiestrogen for the treatment of breast cancer. Cancer (1976) 0.96
Editorial: Large-bowel cancer-The current status of treatment. J Natl Cancer Inst (1976) 0.94
Patterns of failure in small cell carcinoma of the lung. Cancer (1982) 0.92
Combination chemotherapy of advanced Hodgkin's disease. A review. Cancer (1974) 0.91
Streptozotocin and metastatic insulinoma. Ann Intern Med (1971) 0.89
Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial. J Clin Oncol (1987) 0.89
The nitrosoureas--thoughts for the future. Cancer Treat Rep (1976) 0.88
Investigational drugs under study by the United States National Cancer Institute. Cancer Treat Rev (1976) 0.88
An overview of the status of the nitrosoureas in other tumors. Cancer Chemother Rep 3 (1973) 0.87
The chemotherapy of prostatic adenocarcinoma. Ann Intern Med (1980) 0.87
Antiestrogens in the treatment of breast cancer. Cancer Treat Rev (1976) 0.86
Population-based study of small-cell lung cancer. J Clin Oncol (1985) 0.86
The integration of chemotherapy into a combined modality approached to cancer therapy. V. Squamous cell cancer of the head and neck. Cancer Treat Rev (1975) 0.86
Clinical comparison of the nitrosoureas. Cancer (1975) 0.86
The California breast cancer law and government-mandated patient education. CA Cancer J Clin (1982) 0.86
The integration of chemotherapy into combined modality treatment of solid tumors. VIII. Cervical cancer. Cancer Treat Rev (1977) 0.86
Perspectives on research in gynecologic oncology. Cancer (1976) 0.86
Hexamethylmelamine--a new drug with activity in solid tumors. Eur J Cancer (1973) 0.85
Cancer chemotherapy: new developments and changing concepts. Drugs (1980) 0.85
Chemotherapy in advanced breast cancer. Int J Radiat Oncol Biol Phys (1978) 0.83
1,3-bis(2-chloroethyl)-1-nitrosourea (bcnu) and other nitrosoureas in cancer treatment: a review. Adv Cancer Res (1972) 0.83
Gastric cancer: current status of treatment. J Natl Cancer Inst (1977) 0.83
Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs. J Clin Oncol (1984) 0.83
Methyl-CCNU inclinical cancer therapy. Cancer Treat Rev (1974) 0.83
A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine-unresponsive metastatic prostatic carcinoma. Cancer (1985) 0.81
Phase I trial of intravenous L-phenylalanine mustard plus the sensitizer misonidazole. Cancer Res (1983) 0.81
Chromomycin A3, mithramycin, and olivomycin: antitumor antibiotics of related structure. Adv Pharmacol Chemother (1975) 0.81
The interpretation of trials: combined hormonal therapy and chemotherapy in disseminated breast cancer. Breast Cancer Res Treat (1981) 0.81
New drugs on the horizon in bronchogenic carcinoma. Cancer (1972) 0.81
New chemotherapeutic agents--bleomycin and adriamycin. CA Cancer J Clin (1975) 0.80
Cancer treatment today and its impact on drug development, with special emphasis on the phase II clinical trial. J Natl Cancer Inst (1976) 0.80
Integration of chemotherapy into combined modality treatment of solid tumors. 1. The overall strategy. Cancer Treat Rev (1974) 0.80
Current therapies in osteosarcoma. Cancer Treat Rev (1975) 0.80
Adjuvant chemotherapy in osteogenic sarcoma: the triumph that isn't? J Clin Oncol (1984) 0.80
Some thoughts on experimental models and their clinical correlations. Eur J Cancer (1975) 0.80
Chemotherapy and genitourinary oncology. I. Bladder cancer. Cancer Treat Rev (1978) 0.80
Single-agent therapy for Hodgkin's disease. Arch Intern Med (1973) 0.79
Methodology of data reporting in advanced breast cancer trials. Cancer Chemother Pharmacol (1979) 0.79
Immunotherapy of cancer in man: current status and prospectus. Ann N Y Acad Sci (1976) 0.79
Cyclophosphamide in solid tumors. Cancer Treat Rev (1975) 0.78
Chemotherapy of disseminated gastric cancer. A joint effort of the Northern California Oncology Group and the Japanese Gastric Cancer Chemotherapy Group. Cancer (1983) 0.78
Tyrosine kinase inhibitors and signal transduction modulators: Rationale and current status as chemopreventive agents for prostate cancer. Urology (2001) 0.78
Sequential combination of bleomycin and mitomycin in advanced cervical cancer--an American experience: a Northern California Oncology Group study. Cancer Treat Rep (1982) 0.78
Experimental models and their clinical correlations. Natl Cancer Inst Monogr (1977) 0.77
Plant products in cancer chemotherapy. Cancer Treat Rep (1976) 0.77
Current protocol approaches in large bowel cancer. Semin Oncol (1976) 0.77
C.R.O.S. conference on combined modalities chemotherapy/radiotherapy. Hilton Head Island, South Carolina, November 15--18, 1978. Cancer Chemother Pharmacol (1979) 0.77
2,2'-(9,10-anthrylenedimethylene)bis[2-thiopseudourea], dihydrochloride, dihydrate (NSC-56054)--clinical brochure. Cancer Chemother Rep 3 (1968) 0.77
Future directions in the therapy for large bowel cancer. Cancer (1982) 0.76
Peplomycin. Cancer Treat Rev (1984) 0.76
Mitomycin C (NSC-26980)--clinical brochure. Cancer Chemother Rep 3 (1968) 0.76
Clinical considerations in the design of clinical trials. Cancer Treat Rep (1980) 0.76
Treating breast carcinoma. West J Med (1976) 0.75
Planning combined therapy--the interaction of experimental and clinical studies. Cancer Chemother Rep 2 (1974) 0.75
Cancer chemotherapy as it approaches middle age. Cancer Chemother Pharmacol (1978) 0.75
What you can do for your patients with breast cancer. Med Times (1978) 0.75
Historical background of the National Cancer Institute's drug development thrust. Natl Cancer Inst Monogr (1977) 0.75
Screening at the National Cancer Institute. Natl Cancer Inst Monogr (1977) 0.75
Osteogenic sarcoma treatment overview and some comments on interpretation of clinical trial data. Cancer Treat Rep (1978) 0.75
New drugs under clinical evaluation in the United States. Cancer Chemother Pharmacol (1978) 0.75
The strategy of cancer treatment: introduction. Recent Results Cancer Res (1977) 0.75
Phase III studies and the strategy for integrating chemotherapy into a combined modality approach. Natl Cancer Inst Monogr (1977) 0.75
Antitumor antibiotics--thoughts for the future. Recent Results Cancer Res (1978) 0.75
Phase I clinical trials. Natl Cancer Inst Monogr (1977) 0.75
The chemical therapy of breast cancer. Semin Oncol (1974) 0.75
The linear array. Natl Cancer Inst Monogr (1977) 0.75
Phase II clinical trials. Natl Cancer Inst Monogr (1977) 0.75
Adriamycin--friend and foe. Am J Surg Pathol (1977) 0.75
The strategy of cancer treatment: testicular carcinoma. Recent Results Cancer Res (1977) 0.75
Concluding remarks on malignant lymphomas. Recent Results Cancer Res (1978) 0.75
Endometrial cancer: approach to development of effective chemotherapy. Gynecol Oncol (1974) 0.75
The analysis of adjuvant trials. Cancer Treat Rev (1978) 0.75
Some thoughts on experimental screening. Biomedicine (1975) 0.75